Tinlarebant (LBS-008)

Name: Tinlarebant (LBS-008) in Stargardt disease type 1: Prevalence of Stargardt disease type 1
Published: 2026-09-14T15:39:06-04:00

Stargardt disease type 1

Manufacturer: Belite Bio
Regulatory submission: NDA submitted June 2026
Launch: Anticipated in March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Epidemiology

Prevalence of Stargardt disease type 1

2 evidence topics · 2 sources

Estimated U.S. patient population

“STGD1 affects an estimated 53,000 people in the U.S. alone” (opens the source at this quote in a new tab)

Incidence and prevalence: Netherlands nationwide registry: prevalence

“point prevalence in 2018 was approximately 1:22,000‐1:19,000” (opens the source at this quote in a new tab)
“with and without 10% of potentially unregistered cases” (opens the source at this quote in a new tab)